AUTHORS
Mingnan Zhang, Jiarui Zhou2, Min Xiong3, Xingyu Cao, MD4, Jian-Ping Zhang5, Yue Lu, PhD6, Zhijie Wei, MD7, Deyan Liu8, Yanli Zhao9, Peihua (Peggy) Lu, MD10, Ruijuan Sun, MD11
AFFILIATIONS
1 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
2 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
3 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
4 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
5 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
6 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
7 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
8 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
9 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
10 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
11 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
ABSTRACT
Background
RUNX1::RUNX1T1-positive acute myeloid leukemia (AML) is traditionally considered a favorable-risk subtype; however, patients with high-risk features, including measurable residual disease (MRD), KIT mutations, or relapsed/refractory disease, remain at substantial risk of treatment failure. The impact of contemporary allogeneic hematopoietic stem cell transplantation (allo-HSCT) and factors driving long-term survival in this population remain poorly defined.
Methods
We retrospectively analyzed pediatric patients (aged 0–17 years) with high-risk RUNX1::RUNX1T1-positive AML who underwent allo-HSCT at Hebei Yanda Ludaopei Hospital between 2015 and 2024. Clinical outcomes were evaluated from transplantation, including overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). Survival outcomes were estimated using Kaplan-Meier analysis, relapse and NRM were evaluated using competing-risk methods, and outcomes were compared between two transplant eras (2015–2019 vs 2020–2024). Multivariable Cox regression and time-dependent analyses were performed to identify prognostic factors.
Results
A total of 239 patients were included, with a median follow-up of 62.2 months. The median age at transplantation was 10 years. This cohort represented a high-risk population, including 143 patients (59.8%) with pre-HSCT MRD positivity, 64 (26.8%) transplanted beyond CR1, and 32 (13.4%) transplanted with non-remission disease. Haploidentical donors were used in 203 patients (84.9%).
For the entire cohort, the 5-year OS and DFS were 76.9% (95% CI, 70.9–81.8) and 72.4% (95% CI, 66.2–77.7), respectively. Disease control was excellent, with a 5-year CIR of 5.1% (95% CI, 2.8–8.5). The 5-year NRM was 17.9% (95% CI, 13.3–23.1). The cumulative incidences of grade III–IV acute GVHD, chronic GVHD, and TA-TMA were 20.5%, 45.6%, and 3.8%, respectively.
Patients transplanted during 2020–2024 (n=122) and 2015–2019 (n=117) had comparable baseline characteristics and transplant features. Compared with the earlier era, the recent era demonstrated significantly improved 5-year OS (83.4% vs 70.8%) and DFS (77.8% vs 67.4%). This survival improvement was not attributable to reduced relapse, as CIR remained consistently low (4.3% vs 6.0%), but was primarily driven by a marked reduction in NRM (12.4% vs 23.2%). Correspondingly, severe transplant-related complications declined, including grade III–IV acute GVHD (18.0% vs 23.1%), chronic GVHD (42.1% vs 48.9%), and TA-TMA (2.5% vs 5.1%).
In multivariable analysis, post-HSCT MRD positivity was independently associated with inferior overall survival (HR, 3.94; 95% CI, 2.14–6.99; P<0.0001). Time-dependent analyses demonstrated that grade III–IV acute GVHD was strongly associated with increased mortality (HR, 3.21; 95% CI, 1.84–5.52; P<0.0001) and non-relapse mortality (HR, 4.82; 95% CI, 2.56–9.08; P<0.0001), while TA-TMA was also associated with inferior survival (HR, 3.50; 95% CI, 1.18–8.43; P=0.0108).
Conclusion
Allo-HSCT achieved durable disease control and long-term survival in high-risk pediatric RUNX1::RUNX1T1-positive AML, with a 5-year relapse incidence of only 5.1%. Survival improvement over the past decade was primarily driven by reduced transplant-related mortality rather than further reduction in relapse. Continued optimization of GVHD prevention, TA-TMA management, and supportive transplant strategies represents the key pathway to further improve outcomes in this population.
DISCLOSURES
Mingnan Zhang: No relevant conflicts of interest to declare.